Prodia Genomics’ 5 Years of Existence: Pioneering the First Genomic-Based Diagnostic Services in Indonesia with Indonesian Genomic Data

JAKARTA, 17 February 2024 – PT Prodia Widyahusada, Tbk (ticker symbol: PRDA) has been developing predictive, preventive genomic tests since October 2018 and keeps innovating to provide the newest types of genomics tests. Prodia is the first and only laboratory in Indonesia that develops and processes genomic samples on its own. Taking the theme of “Celebrating 5 Years of Genomic Brilliance”, Prodia is committed to offering its customers comprehensive and excellent genomic-based diagnostic services by exploiting the complex and unique genetics of each individual that has been validated and curated using the Indonesian population database.

The event took place at the JW Marriott Hotel Jakarta ballroom and was attended by PT Prodia Widyahusada Tbk’s co-founder and chief commissioner, Drs. Andi Wijaya, PhD, MBA, PT Prodia Widyahusada Tbk’s Business and Marketing Director Dr. Indriyanti Rafi Sukmawati, PT Prodia Widyahusada Tbk’s Business Assistant Vice President Marya Wulandari, SE. MM, PT Prodia Widyahusada Tbk’s Marketing and Account Assistant Vice President Dr. Dwi Yuniati Daulay, M. Kes,. Apt, PT Prodia Widyahusada Tbk’s Product & Scientific Manager Dr. Trilis Yulianti, M.Kes, Prodia’s boards of directors and commissioners, and a number of guests who belong to doctors, customers, and Prodia’s strategic partners.

Prodia Director of Business & Marketing, Dr. Indriyanti Rafi Sukmawati, M.Si., explained that Prodia Genomics helps support Prodia’s concrete efforts to achieve its vision of becoming the leading Next Generation Healthcare Provider in Indonesia. “Prodia Genomics really contributes to raising awareness of the importance of preventive and predictive measures among the general public for a better and higher level of health. In addition, with the advantage of having genomic data sourced directly from the Indonesian people, the results of genomic tests performed at Prodia will be more accurate,” Indriyanti said.

This event used a presentation session format by speakers Prof. Dr. dr, Sidartawan Soegondo, Sp.PD-KEMD, FINASIM, FACE, an internal medicine specialist-diabetes, endocrinology, & metabolism consultant, and Dr. dr. Valentinus Besin, Sp.N, a neurologist. In addition, the event also featured a talk show led by dr. Andhika Respati, Sp.KO, a sports medicine physician and health influencer, along with dr. Arti Indira M.Gizi, Sp.GK., a nutrition specialist. All the speakers emphasized the importance of early detection of health risks that may occur in the body and the role of genomic screening in the transition from conventional medicine to personalized medicine.

On this occasion, Product & Scientific Manager Trilis Yulianti said, “Prodia Genomics is concrete evidence that Prodia provides health services that focus on personalization. In line with the Prodia Genomics tagline, “Everyone is unique”, Prodia understands that human DNA is characterized by its complexity and variation, resulting in different body responses and metabolism in each person. So, we step forward to fulfill our patient’s needs by providing the newest genomic services,” Trilis said.

Genomic tests involve analyzing and understanding the genetic information in the human genome. The procedure involves sampling genetic materials, such as DNA-contained blood. By performing genomic tests domestically, billions of important data and information contained in the genes of each tested individual can be protected, avoiding the transfer of data to other countries or even criminals. Prodia invites the public to raise their awareness of the importance of taking genomic tests at an appropriate health facility.

Overview of Prodia Genomics

Prodia Genomics’ predictive, preventive tests were first launched in 2018, namely CArisk, which can help an individual detect the risk of 13 types of cancer. Then, in 2019, DIArisk test was launched to detect diabetes risk, TENSrisk to detect the risk of hypertension, VASCULArisk to detect the risk of heart disease, Prodia Nutrigenomics to determine the appropriate lifestyle based on genomic profiles, and IMMUNErisk to detect the risk of autoimmune diseases. In 2020, Prodia Bone, Muscle, and Joint Genomics was launched to detect the risk of some diseases affecting the bones, muscles, and joints, and Prodia Skin & Hair Genomics to determine skin and hair health based on genomics, and lastly, Prodia Wellness Genomics.

In 2021, Prodia launched NEUROgenomics to detect the risk of neurological diseases, EYEgenomics to detect the risk of eye disorders, and CardioPGx to determine drug suitability based on genomics. In 2022, Prodia Sport Genomics was launched. This year, Sleep and Stress Genomics will be launched to help an individual determine the best sleep schedule to boost productivity and also detect the risk of stress and how to manage it appropriately.

Through these tests, Prodia is following the paradigm shift in healthcare towards personalized medicine by taking into account the highly variable genetics, environments, and lifestyles to offer personalized solutions. The entire procedure of collecting and processing samples for tests is conducted domestically and supported by laboratory technology and professional staff that meet the qualifications and standards for processing genomic test samples.

******

About PT Prodia Widyahusada Tbk.

Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. From the very beginning, Dr. Andi Widjaja, MBA and the other co-founders have remained committed to delivering the best test results with devoted services.

As the market leader, since 2012, Prodia has been the only laboratory and clinic in Indonesia accredited by the College of American Pathologists (CAP). It implies that Prodia’s test results are equal in quality to those obtained from other international laboratories.

On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol ‘PRDA’. In that corporate action, Prodia offered 187.5 million shares. Accordingly, the fund raised from the Company’s initial public offering (IPO) was Rp1.22 trillion.

As of 31 December 2023, Prodia runs a service network encompassing 295 outlets in 79 cities, 89 districts, and 34 provinces across Indonesia. Some of them are Prodia Health Care (PHC)–a personalized medicine-based wellness clinic–and specialty clinics, including Prodia Children, Prodia Women, and Prodia Senior.

Prodia has also launched Prodia Contact, which includes a call center that can be reached at 1500-830 and an online virtual personal assistant Ask Prodia (TANIA) that can be accessed via WhatsApp: 08551500830, Telegram: @prodia.id, Facebook Messenger: @prodia.id, and Prodia’s Web Widget: www.prodia.co.id. Prodia services can also be accessed via the U by Prodia app, which you can download on the App Store and Play Store.

For more information, visit www.prodia.co.id or contact: